ESRD

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Despite Amplified Use of SGLT2 Inhibitors for Glomerular Diseases, EU and US Nephrologists Express a Continued Strong Desire for New Treatment Options for FSGS Patients, Spherix Reports

Retrieved on: 
Wednesday, September 21, 2022

EXTON, PA., Sept. 21, 2022 /PRNewswire/ -- Focal segmental glomerulosclerosis (FSGS) is one of the leading causes of nephrotic syndrome across the world and is considered the most common glomerular cause of end-stage renal disease (ESRD).1 Spherix has been tracking the evolution of the FSGS market since 2018 to keep a pulse on how nephrologists are treating patients and the perceived potential for products as they make their way through development.

Key Points: 
  • Over the past few months, Spherix has released two reports revealing insights from both US-based and EU5-based nephrologists as a part of its Market Dynamix: Focal Segmental Glomerulosclerosis (FSGS) research services.
  • Of note, Spherix experts found that while most FSGS patients are still confirmed via kidney biopsies, nephrologists are becoming increasingly likely to use genetic testing for diagnosis.
  • In fact, reported use of SGLT2 inhibitors in primary FSGS patients more than doubled year-over-year in both regions captured in these studies, with expectations for continued growth.
  • To gauge pipeline product potential, Spherix assessed awareness, familiarity, desire to have approved, likelihood to prescribe, and estimated patient candidacy for the following assets:

Global End Stage Renal Disease Market Report (2022 to 2030) - Growing Prevalence of Diabetes and Hypertension is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022

The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.

Key Points: 
  • The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.
  • Chronic Kidney Disease (CKD) is one of the major causes of increasing kidney failure rates among patients.
  • Technological advancements in the treatment of renal failure are another factor expediting the market growth for ESRD.
  • End Stage Renal Disease Market Variables, Trends & Scope

Global Dialysis Market Report 2022: Growing Number of Diabetic and Hypertension Patients Fueling Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022

The "Dialysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dialysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global dialysis market reached a value of US$ 104.13 Billion in 2021.
  • The growing number of diabetic and hypertension patients along with the increasing incidences of end-stage renal disease (ESRD) are primarily driving the global dialysis market.
  • Additionally, the introduction of sorbent-based regenerative technology that enables the delivery of high-dose dialysis with a low volume of dialysis solution while removing toxins is expected to drive the global dialysis market in the coming years.

Gold Kidney Health Plan Launches in Arizona

Retrieved on: 
Thursday, September 15, 2022

SCOTTSDALE, Ariz., Sept. 15, 2022 /PRNewswire/ -- Gold Kidney of Arizona, Inc., a subsidiary of Gold Kidney Health Plan has contracted with the Centers of Medicare and Medicaid (CMS) and is launching a Medicare Advantage Chronic-Care Special Needs Plan effective January 1, 2023. Gold Kidney of Arizona will offer the same coverage as Medicare with additional benefits, designed for patients with Chronic Kidney Disease that lead to and include Kidney Failure.

Key Points: 
  • Medicare Health Plan in Arizona specifically designed for Medicare beneficiaries living with Diabetes, Heart Failure, Cardiovascular Disease and End Stage Kidney Disease
    SCOTTSDALE, Ariz., Sept. 15, 2022 /PRNewswire/ -- Gold Kidney of Arizona, Inc., a subsidiary of Gold Kidney Health Plan has contracted with the Centers of Medicare and Medicaid (CMS) and is launching a Medicare Advantage Chronic-Care Special Needs Plan effective January 1, 2023.
  • Gold Kidney of Arizona will offer the same coverage as Medicare with additional benefits, designed for patients with Chronic Kidney Disease that lead to and include Kidney Failure.
  • Gold Kidney of Arizona will begin enrolling members in its new Medicare Advantage plan beginning October 15, 2022.
  • "We are really pleased to offer the Medicare Health Plan in Arizona Intended for Medicare beneficiaries living with chronic conditions that lead to and include kidney failure," said Dave Firdaus, CEO of Gold Kidney Health Plan.

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Retrieved on: 
Monday, September 12, 2022

Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.

Key Points: 
  • Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.
  • It is fantastic to see that the SMC has followed the direction of England and Wales to offer certain highly sensitized patients the opportunity of a life-altering transplant.
  • "We are thrilled that the SMC has recommended Idefirixas the first licensed therapy for highly sensitized kidney patients in Scotland.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

Global Organ Preservation Market Report 2022: Rising Number of Solid Organ Transplants to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022

The global organ preservation market is projected to reach USD 317 million by 2026 from USD 270 million in 2021, at a CAGR of 6.6%.

Key Points: 
  • The global organ preservation market is projected to reach USD 317 million by 2026 from USD 270 million in 2021, at a CAGR of 6.6%.
  • Growth in this market is majorly driven by the increasing incidence of multi-organ failure, the growing geriatric population, the rising number of organ transplants and organ donors, and increasing initiatives to encourage organ donations.
  • Kidneys hold the largest share in the market, by organ type
    Kidneys accounts for a market share in the organ segment.
  • In 2020, the organ transplant centers segment accounted for the largest share of the organ preservation market.

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Retrieved on: 
Tuesday, September 6, 2022

IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (Eledon) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).

Key Points: 
  • IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (Eledon) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).
  • Eledon plans to open U.S. sites under this IND as part of its ongoing global Phase 2a clinical trial evaluating tegoprubart for the treatment of IgAN.
  • Multiple patients in the Phase 2a study have begun receiving treatment with tegoprubart.
  • Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter
    This press release contains forward-looking statements that involve substantial risks and uncertainties.

Global Hemodialysis and Peritoneal Dialysis Market Analysis/Forecast 2022-2028: Market Strategies by Key Players & Shift in Preference of Patients for Home Care Dialysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022

The presence of competitive market players introducing advanced products and services with innovative strategies acts as a future trend of the hemodialysis and peritoneal dialysis market.

Key Points: 
  • The presence of competitive market players introducing advanced products and services with innovative strategies acts as a future trend of the hemodialysis and peritoneal dialysis market.
  • The global hemodialysis and peritoneal dialysis market is segmented on the basis of type, product, and end user.
  • Additionally, the Regents of the University of California report states that various health centers offer quality hemodialysis and peritoneal dialysis services.
  • Such aforementioned factors would highly support the growth of the hemodialysis and peritoneal dialysis market during the forecast period.

Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy

Retrieved on: 
Tuesday, August 23, 2022

According to the FDA, Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fulfill an unmet medical need.

Key Points: 
  • According to the FDA, Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fulfill an unmet medical need.
  • A therapeutic candidate that receives Fast Track designation may be eligible for more frequent interactions with the FDA to discuss the candidates development plan and, if relevant criteria are met, eligibility for Accelerated Approval and Priority Review.
  • MK-2060 is an investigational monoclonal antibody designed to inhibit Factor XI and its ability to activate downstream proteins involved in the blood coagulation cascade.
  • Earlier this year Merck highlighted its broad and growing cardiovascular portfolio and pipeline at an investor event , where MK-2060 was featured.